Literature DB >> 25147230

Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.

Amal Aqul1, Adam M Lopez2, Kenneth S Posey2, Anna M Taylor3, Joyce J Repa4, Dennis K Burns5, Stephen D Turley6.   

Abstract

Cholesteryl ester storage disease (CESD) results from loss-of-function mutations in LIPA, the gene that encodes lysosomal acid lipase (LAL). Hepatomegaly and deposition of esterified cholesterol (EC) in multiple organs ensue. The present studies quantitated rates of synthesis, absorption, and disposition of cholesterol, and whole body cholesterol pool size in a mouse model of CESD. In 50-day-old lal(-/-) and matching lal(+/+) mice fed a low-cholesterol diet, whole animal cholesterol content equalled 210 and 50 mg, respectively, indicating that since birth the lal(-/-) mice sequestered cholesterol at an average rate of 3.2 mg·day(-1)·animal(-1). The proportion of the body sterol pool contained in the liver of the lal(-/-) mice was 64 vs. 6.3% in their lal(+/+) controls. EC concentrations in the liver, spleen, small intestine, and lungs of the lal(-/-) mice were elevated 100-, 35-, 15-, and 6-fold, respectively. In the lal(-/-) mice, whole liver cholesterol synthesis increased 10.2-fold, resulting in a 3.2-fold greater rate of whole animal sterol synthesis compared with their lal(+/+) controls. The rate of cholesterol synthesis in the lal(-/-) mice exceeded that in the lal(+/+) controls by 3.7 mg·day(-1)·animal(-1). Fractional cholesterol absorption and fecal bile acid excretion were unchanged in the lal(-/-) mice, but their rate of neutral sterol excretion was 59% higher than in their lal(+/+) controls. Thus, in this model, the continual expansion of the body sterol pool is driven by the synthesis of excess cholesterol, primarily in the liver. Despite the severity of their disease, the median life span of the lal(-/-) mice was 355 days.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  cholesterol synthesis; esterified cholesterol; hepatomegaly; lysosomal storage disease; sterol balance

Mesh:

Substances:

Year:  2014        PMID: 25147230      PMCID: PMC4200320          DOI: 10.1152/ajpgi.00243.2014

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  58 in total

1.  Effect of feeding psyllium and cholestyramine in combination on low density lipoprotein metabolism and fecal bile acid excretion in hamsters with dietary-induced hypercholesterolemia.

Authors:  S D Turley; B P Daggy; J M Dietschy
Journal:  J Cardiovasc Pharmacol       Date:  1996-01       Impact factor: 3.105

Review 2.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans.

Authors:  J M Dietschy; S D Turley; D K Spady
Journal:  J Lipid Res       Date:  1993-10       Impact factor: 5.922

3.  Neutral lipids and peroxisome proliferator-activated receptor-{gamma} control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice.

Authors:  Xuemei Lian; Cong Yan; Yulin Qin; Lana Knox; Tingyu Li; Hong Du
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

Review 4.  Hepatic uptake of chylomicron remnants.

Authors:  A D Cooper
Journal:  J Lipid Res       Date:  1997-11       Impact factor: 5.922

Review 5.  Receptor-mediated endocytosis: insights from the lipoprotein receptor system.

Authors:  M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

Review 6.  Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.

Authors:  Lin Jia; Jenna L Betters; Liqing Yu
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

7.  Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.

Authors:  Lin Jia; Yinyan Ma; Shunxing Rong; Jenna L Betters; Ping Xie; Soonkyu Chung; Nanping Wang; Weiqing Tang; Liqing Yu
Journal:  J Lipid Res       Date:  2010-08-10       Impact factor: 5.922

Review 8.  Defective cholesterol trafficking in Niemann-Pick C-deficient cells.

Authors:  Kyle B Peake; Jean E Vance
Journal:  FEBS Lett       Date:  2010-04-21       Impact factor: 4.124

9.  Receptor-mediated and bulk-phase endocytosis cause macrophage and cholesterol accumulation in Niemann-Pick C disease.

Authors:  Benny Liu; Chonglun Xie; James A Richardson; Stephen D Turley; John M Dietschy
Journal:  J Lipid Res       Date:  2007-05-02       Impact factor: 5.922

10.  Protein replacement therapy partially corrects the cholesterol-storage phenotype in a mouse model of Niemann-Pick type C2 disease.

Authors:  Gitte Krogh Nielsen; Frederik Dagnaes-Hansen; Ida Elisabeth Holm; Steve Meaney; Derek Symula; Niels Trolle Andersen; Christian Würtz Heegaard
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

View more
  15 in total

Review 1.  Genetically modified mouse models to study hepatic neutral lipid mobilization.

Authors:  Guenter Haemmerle; Achim Lass
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-06-05       Impact factor: 5.187

2.  LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo.

Authors:  Kristin L Bowden; Joshua A Dubland; Teddy Chan; You-Hai Xu; Gregory A Grabowski; Hong Du; Gordon A Francis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

3.  Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver.

Authors:  Adam M Lopez; Kenneth S Posey; Stephen D Turley
Journal:  Biochem Biophys Res Commun       Date:  2014-10-18       Impact factor: 3.575

4.  Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function.

Authors:  Adam M Lopez; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-07       Impact factor: 4.052

5.  Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.

Authors:  Jen-Chieh Chuang; Adam M Lopez; Stephen D Turley
Journal:  Biochem Pharmacol       Date:  2017-03-18       Impact factor: 5.858

6.  Ontogenesis and Modulation of Intestinal Unesterified Cholesterol Sequestration in a Mouse Model of Niemann-Pick C1 Disease.

Authors:  Adam M Lopez; Charina M Ramirez; Anna M Taylor; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Dig Dis Sci       Date:  2019-07-17       Impact factor: 3.199

Review 7.  Breaking fat: The regulation and mechanisms of lipophagy.

Authors:  Ryan J Schulze; Aishwarya Sathyanarayan; Douglas G Mashek
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-06-20       Impact factor: 4.698

8.  Molecular markers of brain cholesterol homeostasis are unchanged despite a smaller brain mass in a mouse model of cholesteryl ester storage disease.

Authors:  Amal A Aqul; Charina M Ramirez; Adam M Lopez; Dennis K Burns; Joyce J Repa; Stephen D Turley
Journal:  Lipids       Date:  2021-10-07       Impact factor: 1.880

9.  PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice.

Authors:  Adam M Lopez; Jen-Chieh Chuang; Kenneth S Posey; Taichi Ohshiro; Hiroshi Tomoda; Lawrence L Rudel; Stephen D Turley
Journal:  J Pharmacol Exp Ther       Date:  2015-08-17       Impact factor: 4.030

10.  Impact of loss of SOAT2 function on disease progression in the lysosomal acid lipase-deficient mouse.

Authors:  Adam M Lopez; Jen-Chieh Chuang; Stephen D Turley
Journal:  Steroids       Date:  2017-12-13       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.